# BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

> **NCT00126646** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 24 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** BL22 immunotoxin
- **PROCEDURE:** antibody-drug conjugate therapy
- **PROCEDURE:** immunotoxin therapy

## Key facts

- **NCT ID:** NCT00126646
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2009-03
- **Final completion:** 2009-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126646, "BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00126646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*